Lp(a) Testing for Men in 2026: The Genetic Cholesterol Number Most American Men Have Never Checked

You have had your cholesterol checked every year at your annual physical since you turned 30. You know your LDL, you know your HDL, you know your triglycerides, and if you are paying attention you know your ApoB. There is one more number on the lipid panel that almost no American man under 50 has ever been tested for, that one in five carries at a dangerous level, and that does not change with diet, exercise, statins or weight loss. It is called lipoprotein(a), written as Lp(a) and pronounced "L-P-little-a," and 2026 is the year it stops being a curiosity and starts being a screening recommendation.

What Lp(a) Actually Is

Lp(a) is a low-density lipoprotein particle with an extra protein, apolipoprotein(a), wrapped around it. The structure is similar enough to plasminogen — the body's natural clot dissolver — that high levels interfere with the clot-clearing machinery on the inside of your arteries. The particle is also intensely atherogenic in its own right; it deposits cholesterol into arterial walls faster than ordinary LDL and accelerates the formation of plaques. The combination is uniquely dangerous: an Lp(a) particle is both better at building plaque and worse at letting your body clean up the clot when a plaque eventually ruptures.

The level you are born with is essentially the level you will die with. Lp(a) is roughly 90% genetically determined. Lifestyle does almost nothing to it. Statins do almost nothing to it — some studies actually show a small increase. PCSK9 inhibitors lower it modestly, around 25%. Niacin can lower it but the side-effect profile is rough enough that nobody prescribes it for that purpose anymore. Until 2026, there was no specific therapy. That is now changing.

Why You Should Know Your Number

Roughly 20% of Americans — about 64 million people — have an Lp(a) level above 50 mg/dL, the threshold at which cardiovascular risk meaningfully rises. Above 100 mg/dL, lifetime risk of premature heart attack and stroke roughly doubles. The men who have a heart attack in their 40s with no obvious risk factors — normal weight, normal LDL, no smoking, regular exercise — are disproportionately drawn from the high-Lp(a) population. The lab test is cheap (around $15 to $50 depending on insurance), takes the same blood draw as your normal lipid panel, and only needs to be done once in a lifetime. Most American men have still never had it.

The reason is structural. Lp(a) is not part of the standard lipid panel that primary care orders. You have to ask for it specifically, by name, and your doctor has to add it to the order. Until the American Heart Association updated its guidance in late 2024 to recommend at least one Lp(a) measurement in adulthood for everyone, most physicians did not bring it up. Many still do not.

How to Get the Test

Three paths, in order of cost:

• Through your primary care physician. Ask explicitly: "I would like an Lp(a) test, ideally measured in nmol/L rather than mg/dL." Most major insurers cover it for at least a one-time screening under the updated AHA guidance, particularly if you have a family history of early heart disease. Out-of-pocket cost if not covered: $25 to $75.
• Through a direct-to-consumer lab. Quest, Labcorp, Ulta Lab Tests, Marek Health and a half-dozen telehealth services will order the test without a primary care visit. Expect to pay $30 to $90, get results in 3 to 5 business days, and receive a PDF you can hand to any future doctor.
• As part of a comprehensive cardiovascular workup. If you are 40 or older, getting an Lp(a), an ApoB, a fasting insulin and a coronary artery calcium scan in the same month gives you a more complete picture of your cardiovascular trajectory than any number of annual physicals ever will. Total out-of-pocket cost: $400 to $700.

Reading the Number

Lp(a) is reported either in mg/dL or in nmol/L. The two units are not interchangeable and conversion factors vary by laboratory, which is why the nmol/L measurement is preferred by lipidologists. Rough thresholds:

• Below 75 nmol/L (or under 30 mg/dL): normal. No specific action.
• 75 to 125 nmol/L (30 to 50 mg/dL): borderline. Worth managing the other modifiable risk factors more aggressively — LDL, ApoB, blood pressure, weight, smoking.
• Above 125 nmol/L (above 50 mg/dL): elevated. Cardiovascular risk meaningfully increased. Aggressive management of every other lipid number is now medically appropriate, and screening of first-degree relatives is warranted.
• Above 250 nmol/L (above 100 mg/dL): high. Consider a coronary artery calcium scan, a cardiologist referral, and — once the new therapies arrive — early discussion of treatment.

What's Actually Changing in 2026

Two specific Lp(a)-lowering therapies are in late-stage trials and expected to reach the FDA review timeline in 2026 and 2027. Pelacarsen (Novartis) and olpasiran (Amgen) are injected nucleic-acid drugs that lower Lp(a) by 75 to 90 percent. The cardiovascular outcomes trials reading out in 2027 and 2028 will determine whether that translates into fewer heart attacks. If they do, the standard of care for high-Lp(a) men will look very different by 2029. The men who have already been tested and know their number will be the first ones in line.

The Action This Week

The next time you are at a routine blood draw — annual physical, life-insurance exam, the lab draw before a colonoscopy, anything — ask for the Lp(a) test added on. If your insurance does not cover it, pay the $40 yourself. The result lives on your record for the rest of your life. If your number is low, you have eliminated a major source of unknown cardiovascular risk. If it is high, you have time — possibly a decade or more — to manage the rest of your cardiovascular profile aggressively, and you will be ready when the new therapies arrive. The men who get hit hardest by this lipid are the ones who never knew it existed.